BIOMAT Database Logo BIOMAT Database Logo

Six novel MEN1 gene mutations in sporadic parathyroid tumors. 2000

F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, Università di Pisa, Pisa, Italy.

We report nine mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in sporadic parathyroid adenomas. Six of them have not previously been described: E60X, P32R, 261delA, 934+2T-->G, S443P, and 1593insC. The tissue samples were initially submitted to LOH analysis at 11q13 followed by SSCP screening of LOH-positive samples. Mutations were identified by direct sequencing and subcloning. Three (E60X, P32R, and 261delA) were in exon 2, one (934+2bp) in the splice junction of exon 5, one (S443P) in exon 9, and one (1593insC) in exon 10. The 3 mutations in exon 2 were associated with loss and/or creation of a restriction site. The corresponding germline sequence of the MEN1 gene was normal. Most mutations would likely result in a nonfunctional menin protein, and therefore in the loss of a tumor suppressor protein.

UI MeSH Term Description Entries
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010282 Parathyroid Neoplasms Tumors or cancer of the PARATHYROID GLANDS. Cancer of Parathyroid,Parathyroid Cancer,Cancer of the Parathyroid,Neoplasms, Parathyroid,Parathyroid Adenoma,Parathyroid Carcinoma,Adenoma, Parathyroid,Adenomas, Parathyroid,Cancer, Parathyroid,Cancers, Parathyroid,Carcinoma, Parathyroid,Carcinomas, Parathyroid,Neoplasm, Parathyroid,Parathyroid Adenomas,Parathyroid Cancers,Parathyroid Carcinomas,Parathyroid Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016147 Genes, Tumor Suppressor Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible. Antioncogenes,Cancer Suppressor Genes,Emerogenes,Genes, Cancer Suppressor,Genes, Growth Suppressor,Genes, Metastasis Suppressor,Growth Suppressor Genes,Metastasis Suppressor Genes,Tumor Suppressor Genes,Anti-Oncogenes,Genes, Onco-Suppressor,Oncogenes, Recessive,Tumor Suppressing Genes,Anti Oncogenes,Anti-Oncogene,Antioncogene,Cancer Suppressor Gene,Emerogene,Gene, Cancer Suppressor,Gene, Growth Suppressor,Gene, Metastasis Suppressor,Gene, Onco-Suppressor,Gene, Tumor Suppressing,Gene, Tumor Suppressor,Genes, Onco Suppressor,Genes, Tumor Suppressing,Growth Suppressor Gene,Metastasis Suppressor Gene,Onco-Suppressor Gene,Onco-Suppressor Genes,Oncogene, Recessive,Recessive Oncogene,Recessive Oncogenes,Suppressor Gene, Cancer,Suppressor Gene, Growth,Suppressor Gene, Metastasis,Suppressor Genes, Cancer,Suppressor Genes, Growth,Suppressor Genes, Metastasis,Tumor Suppressing Gene,Tumor Suppressor Gene
D016254 Mutagenesis, Insertional Mutagenesis where the mutation is caused by the introduction of foreign DNA sequences into a gene or extragenic sequence. This may occur spontaneously in vivo or be experimentally induced in vivo or in vitro. Proviral DNA insertions into or adjacent to a cellular proto-oncogene can interrupt GENETIC TRANSLATION of the coding sequences or interfere with recognition of regulatory elements and cause unregulated expression of the proto-oncogene resulting in tumor formation. Gene Insertion,Insertion Mutation,Insertional Activation,Insertional Mutagenesis,Linker-Insertion Mutagenesis,Mutagenesis, Cassette,Sequence Insertion,Viral Insertional Mutagenesis,Activation, Insertional,Activations, Insertional,Cassette Mutagenesis,Gene Insertions,Insertion Mutations,Insertion, Gene,Insertion, Sequence,Insertional Activations,Insertional Mutagenesis, Viral,Insertions, Gene,Insertions, Sequence,Linker Insertion Mutagenesis,Mutagenesis, Linker-Insertion,Mutagenesis, Viral Insertional,Mutation, Insertion,Mutations, Insertion,Sequence Insertions

Related Publications

F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Biallelic inactivation by somatic mutations of the MEN1 gene in sporadic parathyroid tumors.
January 2002, Cancer letters,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Alterations of the MEN1 gene in sporadic parathyroid tumors.
August 1998, The Journal of clinical endocrinology and metabolism,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation.
November 1999, Pathology international,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors.
May 2000, Journal of endocrinological investigation,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors.
July 1999, Cancer letters,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors.
October 2000, Cancer research,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.
December 1997, Human molecular genetics,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
MEN1 gene mutations are a rare event in patients with sporadic neuroendocrine tumors.
August 2002, European journal of internal medicine,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
Lack of MEN1 gene mutations in 27 sporadic insulinomas.
April 2000, European journal of clinical investigation,
F Cetani, and E Pardi, and A Giovannetti, and P Cerrai, and S Borsari, and E Vignali, and A Picone, and L Cianferotti, and P Miccoli, and A Pinchera, and C Marcocci
MEN1 gene mutations in 12 MEN1 families and their associated tumors.
October 1998, European journal of endocrinology,
Copied contents to your clipboard!